Novartis is advancing a major expansion of its U.S. pharmaceutical manufacturing capacity with the development of a flagship hub in North Carolina’s Research Triangle region. The project forms part of the Swiss drugmaker’s broader $23 billion investment plan across the United States over five years and is designed to centralize end-to-end production for medicines serving the U.S. market.

The more than 700,000 square foot campus will have facilities in Morrisville and Durham alongside an expansion of an existing site. The aim of the build-out is to centralize end-to-end drug manufacturing for the US market. Novartis new hub will open between 2027 and 2028. The project is also expected to create around 700 direct jobs by 2030 and support more than 3,000 indirect positions across Novartis’ US supply chain. This will strengthen its production of key medicines and reinforce the company’s reach in the US pharmaceutical supply.

Why North Carolina

Novartis’ decision to expand in Durham and Morrisville reinforces North Carolina’s position as one of the United States’ leading life sciences manufacturing hubs. The Research Triangle region offers proximity to major research universities, a deep biopharmaceutical workforce, established contract manufacturing networks, and access to East Coast transportation infrastructure. Over the past two decades, the area has evolved from a research-focused ecosystem into a full-scale production corridor capable of supporting large-volume commercial drug manufacturing.

Project Overview

Novartis’ North Carolina manufacturing hub is central to the company’s broader investment plan in the US. The US has also seen a rising demand for medicines and a heightened focus on domestic supply chain security. The project will also bring together several therapeutic manufacturing capabilities, including biologics, sterile packaging and solid dosage tablets under one roof. Novartis will also be able to scale its production in oncology, immunology, neuroscience and other key disease areas in the US. By producing key medicines for patients in the US, Novartis also intends to substantially reduce reliance on overseas production and accelerate delivery timelines.

The involvement of US officials at the ground breaking ceremony, including North Carolina Governor Josh Stein and the Commissioner of the Food and Drug Administration (FDA) also points toward broader public sector interest in strengthening America’s pharmaceutical manufacturing. This could also extend to enhancing the health security of Americans, especially with new build-outs by Merck Elkton in Virginia and Eli Lilly in Houston.

Outlook on Novartis North Carolina Manufacturing Hub

Construction of the Novartis manufacturing hub in North Carolina is underway. Commissioning is targeted for late 2027 through 2028 (as aforementioned).

Once operational, the manufacturing complex in the Research Triangle region will provide manufacturing capabilities, alongside supporting jobs, talent, and economic growth. The integration of new facilities in Durham – for biologics and sterile packaging, with the Morrisville site – for solid dosage tablets and capsules, and expansion of existing operations will also open up US supply chain efficiency.

What “End-to-End Manufacturing” Means in Practice

By integrating biologics production, sterile fill-finish operations, and solid dosage manufacturing across connected facilities, the hub is designed to consolidate multiple stages of the pharmaceutical value chain within the United States. End-to-end capability reduces reliance on cross-border production handoffs, shortens lead times between drug substance and finished product, and enhances quality oversight. For patients, this translates into improved supply continuity and potentially faster delivery of approved therapies.

Biologics and Advanced Therapies at the Core

The inclusion of biologics manufacturing is particularly significant. Biologic medicines — which include complex therapies used in oncology, immunology, and rare diseases — require specialized production environments, sterile processing, and temperature-controlled logistics. Expanding domestic biologics capacity strengthens the resilience of high-value drug supply chains and supports growing demand for advanced therapies in the U.S. healthcare market.

Part of a Broader Shift Toward Domestic Supply Security

The North Carolina hub reflects a wider industry movement toward localized pharmaceutical production following global supply disruptions in recent years. Major drugmakers have increasingly invested in U.S.-based facilities to reduce exposure to international bottlenecks and reinforce regulatory alignment with federal agencies. By consolidating manufacturing capabilities within the country, companies aim to improve supply chain stability while positioning themselves for long-term growth in key therapeutic areas.

The Novartis hub is part of a broader pattern of large-scale capital investment reshaping North Carolina’s economy. Recent projects in logistics and advanced manufacturing — including an $860 million grocery distribution center in Burlington — underscore the state’s expanding footprint across both life sciences and supply chain infrastructure. Together, these developments highlight North Carolina’s growing role as a strategic production and distribution corridor in the southeastern United States.

The US$23 billion expansion plan by Novartis in the US also includes other parallel investments such as a new biomedical research hub in San Diego and expanded radioligand therapy production across multiple states.

Novartis North Carolina Flagship Manufacturing Hub Project Factsheet

Developer: Novartis AG

Location: Durham and Morrisville in North Carolina

Size: 700,000 square feet

Project Utility: Integrated manufacturing hub for drug production, packaging and end-to-end operations.

Key Focus: Biologics manufacturing, sterile packaging, solid dosage tablets, capsules, and expanded fill-finish capabilities.

Direct Jobs Created: 700 by 2030

Indirect Jobs Supported: 3,000 across supply chain.

Financial Backing: Part of Novartis’ US$23 billion investment over five years.

Expected Completion Date: 2027 to 2028

Project Timeline

November 2025: Novartis plans to expand manufacturing footprint in North Carolina. The pharma giant also outlines scope of new facilities.

December 2025: Official ground breaking ceremony held with senior executives, FDA bosses and state officials. Construction commences.

2026 to 2027: Construction to continue. Equipping and commissioning phases to progress. Also expected is workforce recruitment.

Late 2027 to 2028: Hub to start operations.